Bérubé Marie, Poirier Donald
Medicinal Chemistry Division, Oncology and Molecular Endocrinology Research Center and Université Laval, Centre Hospitalier Universitaire de Québec, Pavillon CHUL, 2705 Laurier Boulevard, Quebec, Qc, G1V 4G2, Canada.
Org Lett. 2004 Sep 2;6(18):3127-30. doi: 10.1021/ol048820u.
[structure: see text] The inhibitor of type 1 17beta-hydroxysteroid dehydrogenase EM-1745 (1) exhibits affinity for both the substrate (estrone or estradiol) and the cofactor (NAD(P)H) binding domains. However, to increase its bioavailability, this compound needs to be simplified. The efficient and convergent synthesis of simplified substrate/cofactor hybrid inhibitors (compounds 2) involving a cross-metathesis and a Sonogashira coupling reaction as key steps is described. Compounds 2a-c were also tested as enzyme inhibitors and compared to EM-1745.
[结构:见原文] 1型17β-羟基类固醇脱氢酶抑制剂EM-1745(1)对底物(雌酮或雌二醇)和辅因子(NAD(P)H)结合域均具有亲和力。然而,为提高其生物利用度,该化合物需要进行简化。本文描述了以交叉复分解反应和Sonogashira偶联反应为关键步骤,高效且汇聚式合成简化的底物/辅因子混合抑制剂(化合物2)的方法。还对化合物2a - c作为酶抑制剂进行了测试,并与EM-1745进行了比较。